WO1997016452A1
(en)
|
1995-11-01 |
1997-05-09 |
Novartis Ag |
Purine derivatives and processes for their preparation
|
FR2741881B1
(fr)
*
|
1995-12-01 |
1999-07-30 |
Centre Nat Rech Scient |
Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
|
US5866702A
(en)
*
|
1996-08-02 |
1999-02-02 |
Cv Therapeutics, Incorporation |
Purine inhibitors of cyclin dependent kinase 2
|
US6794390B2
(en)
*
|
1996-08-02 |
2004-09-21 |
Cv Therapeutics, Inc. |
Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
|
US6790958B2
(en)
*
|
1996-08-02 |
2004-09-14 |
Robert T. Lum |
Purine inhibitors of cyclin dependent kinase 2 & IKBA
|
US6495579B1
(en)
|
1996-12-02 |
2002-12-17 |
Angiotech Pharmaceuticals, Inc. |
Method for treating multiple sclerosis
|
WO1998039007A1
(en)
|
1997-03-03 |
1998-09-11 |
Board Of Regents, The University Of Texas System |
Supression of cyclin kinase 2 activity for prevention and treatment of dna viral infections
|
WO1999007705A1
(en)
*
|
1997-08-07 |
1999-02-18 |
The Regents Of The University Of California |
Purine inhibitor of protein kinases, g proteins and polymerases
|
EP1007684A2
(en)
*
|
1997-09-05 |
2000-06-14 |
CropDesign N.V. |
Method and means for modulating plant cell cycle proteins and their use in controlling plant cell growth
|
US7265267B1
(en)
|
1997-09-16 |
2007-09-04 |
Cropdesign N.V. |
Cyclin-dependent kinase inhibitors and uses thereof
|
EP2194131A3
(en)
*
|
1997-09-16 |
2010-09-22 |
CropDesign N.V. |
Cyclin-dependent kinase inhibitors and uses thereof
|
US6710227B1
(en)
|
1998-09-16 |
2004-03-23 |
Cropdesign N.V. |
Cyclin-dependent kinase inhibitors and uses thereof
|
JP2001520887A
(ja)
*
|
1997-10-24 |
2001-11-06 |
クロップデザイン エヌ.ブイ. |
新規な分裂促進性サイクリンおよびその使用
|
EP0911634A1
(en)
*
|
1997-10-24 |
1999-04-28 |
Het Nederlands Kanker Instituut |
Pharmaceutical uses of CDK-2 regulators
|
KR100568657B1
(ko)
*
|
1998-02-26 |
2006-04-07 |
아벤티스 파마슈티칼스 인크 |
6,9-이치환 2-[트랜스-(4-아미노시클로헥실)아미노]퓨린
|
US6642231B2
(en)
*
|
1998-02-26 |
2003-11-04 |
Aventis Pharmaceuticals Inc. |
6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
|
HUP0100931A3
(en)
*
|
1998-02-26 |
2002-08-28 |
Aventis Pharma Inc |
6,9-disubstituted 2-[trans-(-aminocyclohexyl)amino]purines and pharmaceutical compositions containing them
|
US6479487B1
(en)
*
|
1998-02-26 |
2002-11-12 |
Aventis Pharmaceuticals Inc. |
6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
|
US6703395B2
(en)
*
|
1998-03-04 |
2004-03-09 |
Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic |
Cyclin dependent kinase inhibitor
|
US6221873B1
(en)
*
|
1998-03-04 |
2001-04-24 |
Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic |
Cyclin dependent kinase inhibitor
|
GB9806739D0
(en)
*
|
1998-03-28 |
1998-05-27 |
Univ Newcastle Ventures Ltd |
Cyclin dependent kinase inhibitors
|
US6664439B1
(en)
|
1998-04-28 |
2003-12-16 |
The Procter & Gamble Company |
Absorbent articles with distribution materials positioned underneath storage material
|
WO2000021550A2
(en)
*
|
1998-10-13 |
2000-04-20 |
President And Fellows Of Harvard College |
Methods and compositions for treating neurodegenerative diseases
|
WO2000033657A1
(en)
*
|
1998-12-04 |
2000-06-15 |
Cropdesign N.V. |
Method to identify regulators of cdk activity
|
CZ27399A3
(cs)
*
|
1999-01-26 |
2000-08-16 |
Ústav Experimentální Botaniky Av Čr |
Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
|
AU2004200192B2
(en)
*
|
1999-02-01 |
2006-11-16 |
Gilead Palo Alto, Inc. |
Purine inhibitors of cyclin dependent kinase 2 and 1k-Aa
|
BR0007919A
(pt)
*
|
1999-02-01 |
2002-04-09 |
Cv Therapeutics Inc |
Composição purina 2,6,9-trisubstituìda
|
EP1026251A3
(en)
*
|
1999-02-03 |
2000-09-06 |
Pfizer Products Inc. |
Transgenic animals expressing human P25
|
GB9903762D0
(en)
|
1999-02-18 |
1999-04-14 |
Novartis Ag |
Organic compounds
|
US6969720B2
(en)
|
1999-03-17 |
2005-11-29 |
Amr Technology, Inc. |
Biaryl substituted purine derivatives as potent antiproliferative agents
|
US6627633B2
(en)
*
|
1999-03-17 |
2003-09-30 |
Albany Molecular Research, Inc. |
6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
|
FR2793794B1
(fr)
*
|
1999-05-21 |
2001-07-27 |
Hoechst Marion Roussel Inc |
Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
|
WO2001049688A1
(en)
*
|
2000-01-07 |
2001-07-12 |
Universitaire Instelling Antwerpen |
Purine derivatives, process for their preparation and use thereof
|
US20040224958A1
(en)
*
|
2000-01-27 |
2004-11-11 |
Booth Richard John |
Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
|
FR2806626B1
(fr)
*
|
2000-03-22 |
2003-11-28 |
Centre Nat Rech Scient |
Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
|
KR100423899B1
(ko)
|
2000-05-10 |
2004-03-24 |
주식회사 엘지생명과학 |
세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
|
US20040254094A1
(en)
*
|
2000-10-11 |
2004-12-16 |
The Trustees Of University Of Pennsylvania And Board Of Regents |
Suppression of cyclin kinase activity for prevention and treatment of infections
|
US6861524B2
(en)
|
2000-10-31 |
2005-03-01 |
Aventis Pharmaceuticals Inc. |
Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
|
FR2818642B1
(fr)
*
|
2000-12-26 |
2005-07-15 |
Hoechst Marion Roussel Inc |
Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
|
ATE301123T1
(de)
*
|
2001-06-27 |
2005-08-15 |
Cyclacel Ltd |
2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
|
US6812232B2
(en)
|
2001-09-11 |
2004-11-02 |
Amr Technology, Inc. |
Heterocycle substituted purine derivatives as potent antiproliferative agents
|
US6667311B2
(en)
|
2001-09-11 |
2003-12-23 |
Albany Molecular Research, Inc. |
Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
|
CA2463563A1
(en)
*
|
2001-10-12 |
2003-04-17 |
Irm Llc |
Kinase inhibitor scaffolds and methods for their preparation
|
US20050222054A1
(en)
*
|
2002-03-27 |
2005-10-06 |
Cyclacel Limited |
Combination comprising a CDK inhibitor and doxorubicin
|
AU2003279690A1
(en)
*
|
2002-06-27 |
2004-01-19 |
F. Hoffmann-La Roche Ag |
Synthesis of purine derivatives
|
GB0219052D0
(en)
*
|
2002-08-15 |
2002-09-25 |
Cyclacel Ltd |
New puring derivatives
|
GB0219054D0
(en)
*
|
2002-08-15 |
2002-09-25 |
Cyclacel Ltd |
New purine derivatives
|
GB0219746D0
(en)
*
|
2002-08-23 |
2002-10-02 |
Inst Of Ex Botany Ascr |
Azapurine derivatives
|
AU2003272503A1
(en)
*
|
2002-09-17 |
2004-04-08 |
University Of Utah Research Foundation |
Methods and compositions related to inhibiting nuclear envelope breakdown
|
BR0316021A
(pt)
*
|
2002-11-06 |
2005-09-27 |
Cyclacel Ltd |
Comibinação compreendendo um inibidor de cdk e cisplatina
|
ES2318202T3
(es)
*
|
2002-11-06 |
2009-05-01 |
Cyclacel Limited |
Combinacion que comprende docetaxel y un inhibidor de cdk.
|
GB0225873D0
(en)
*
|
2002-11-06 |
2002-12-11 |
Cyclacel Ltd |
Combination
|
AU2003302747A1
(en)
*
|
2002-12-17 |
2004-07-09 |
Centre National De La Recherche Scientifique (Cnrs) |
Use of purine derivatives for inducing differentiation of supernumerary hair cells and deiters' cells in the developing organ of corti for treating deafness
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
EP1444982A1
(de)
*
|
2003-02-06 |
2004-08-11 |
Merckle Gmbh |
Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
|
GB0307640D0
(en)
*
|
2003-04-02 |
2003-05-07 |
Cyclacel Ltd |
Markers
|
GB0315259D0
(en)
*
|
2003-06-30 |
2003-08-06 |
Cyclacel Ltd |
Use
|
US20070287718A1
(en)
*
|
2003-11-06 |
2007-12-13 |
Green Simon R |
Methods for the Treatment of Multiple Myeloma Using Roscovitine
|
EP2277595A3
(en)
|
2004-06-24 |
2011-09-28 |
Novartis Vaccines and Diagnostics, Inc. |
Compounds for immunopotentiation
|
JP5117189B2
(ja)
|
2004-08-27 |
2013-01-09 |
サイクラセル リミテッド |
プリン及びピリミジンcdk阻害剤、並びに自己免疫疾患の治療のためのそれらの使用
|
JP2008515939A
(ja)
|
2004-10-13 |
2008-05-15 |
エフ.ホフマン−ラ ロシュ アーゲー |
Cdk2及び血管形成の阻害剤として、及び乳癌、結腸癌及び前立腺癌の治療に有用な2置換ピラゾロベンゾジアゼピン
|
FR2876583B1
(fr)
*
|
2004-10-15 |
2007-04-13 |
Centre Nat Rech Scient Cnrse |
Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
|
CA2594477C
(en)
|
2005-01-21 |
2016-07-12 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
CA2624025A1
(en)
*
|
2005-10-14 |
2007-04-19 |
F. Hoffmann-La Roche Ag |
Regimen of administration for 5-(2-chlorophenyl)-1 ,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo [3, 4.-b] [1, 4] benzodiazepine
|
US20070110751A1
(en)
*
|
2005-10-25 |
2007-05-17 |
Maclellan Robb |
Compositions and methods for reducing infarct size
|
RU2432362C2
(ru)
|
2005-11-30 |
2011-10-27 |
Эбботт Лэборетриз |
Моноклональные антитела и их применения
|
PT2289909E
(pt)
|
2005-11-30 |
2015-02-10 |
Abbvie Inc |
Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
FR2899107B1
(fr)
*
|
2006-03-30 |
2008-06-13 |
Neurokin Entpr Unipersonnelle |
Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
|
TW200808739A
(en)
|
2006-04-06 |
2008-02-16 |
Novartis Vaccines & Diagnostic |
Quinazolines for PDK1 inhibition
|
UA93548C2
(uk)
|
2006-05-05 |
2011-02-25 |
Айерем Елелсі |
Сполуки та композиції як модулятори хеджхогівського сигнального шляху
|
JP5528807B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
JP5528806B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
ES2402907T3
(es)
*
|
2006-10-19 |
2013-05-10 |
Genzyme Corporation |
Roscovitina para el tratamiento de ciertas enfermedades quísticas
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
WO2008104386A2
(en)
*
|
2007-02-27 |
2008-09-04 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
CA2682019C
(en)
*
|
2007-03-28 |
2016-08-09 |
Neurosearch A/S |
Purinyl derivatives and their use as potassium channel modulators
|
US20120004246A1
(en)
*
|
2007-03-28 |
2012-01-05 |
Neurosearch A/S |
Purinyl derivatives and their use as potassium channel modulators
|
GB0706632D0
(en)
*
|
2007-04-04 |
2007-05-16 |
Cyclacel Ltd |
New purine derivatives
|
GB0706633D0
(en)
*
|
2007-04-04 |
2007-05-16 |
Cyclacel Ltd |
Combination
|
CZ300774B6
(cs)
*
|
2007-10-05 |
2009-08-05 |
Univerzita Palackého |
Substituované 6-(alkylbenzylamino)purinové deriváty pro použití jako antagonisté cytokininových receptoru a prípravky obsahující tyto slouceniny
|
PA8809001A1
(es)
|
2007-12-20 |
2009-07-23 |
Novartis Ag |
Compuestos organicos
|
JP2011207764A
(ja)
*
|
2008-07-29 |
2011-10-20 |
Univ Of Tokyo |
Cdk阻害剤によるc型肝炎ウイルスの複製抑制
|
PE20100362A1
(es)
|
2008-10-30 |
2010-05-27 |
Irm Llc |
Derivados de purina que expanden las celulas madre hematopoyeticas
|
CZ302122B6
(cs)
*
|
2009-01-28 |
2010-10-20 |
Univerzita Palackého v Olomouci |
Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
|
CZ302623B6
(cs)
*
|
2009-04-22 |
2011-08-03 |
Univerzita Palackého |
Oxalátokomplexy platiny s deriváty N6-benzyladeninu, zpusob jejich prípravy a použití techto komplexu jako léciv v protinádorové terapii
|
FR2945747A1
(fr)
|
2009-05-25 |
2010-11-26 |
Centre Nat Rech Scient |
Composition pharmaceutique antitumorale comprenant un inhibiteur de cdks et un inhibiteur de la croissance cellulaire
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
ES2684475T3
(es)
|
2010-04-15 |
2018-10-03 |
Abbvie Inc. |
Proteínas que se unen a beta amiloide
|
EP2580320B1
(en)
|
2010-06-14 |
2018-08-01 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
CA2808187A1
(en)
|
2010-08-14 |
2012-02-23 |
Abbvie Inc. |
Amyloid-beta binding proteins
|
AU2012213080B2
(en)
|
2011-01-31 |
2014-03-27 |
Novartis Ag |
Novel heterocyclic derivatives
|
WO2012142029A2
(en)
|
2011-04-10 |
2012-10-18 |
Florida A&M University |
Serms for the treatment of estrogen receptor-mediated disorders
|
EP2562265A1
(en)
|
2011-08-22 |
2013-02-27 |
Lead Discovery Center GmbH |
Susceptibility to selective CDK9 inhibitors
|
EP2561867A1
(en)
|
2011-08-22 |
2013-02-27 |
Lead Discovery Center GmbH |
CDK9 inhibitors in the treatment of midline carcinoma
|
PT2771342T
(pt)
|
2011-10-28 |
2016-08-17 |
Novartis Ag |
Derivados de purina e o seu uso no tratamento de doença
|
WO2013113762A1
(en)
|
2012-01-31 |
2013-08-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for predicting the risk of having a cutaneous melanoma in a subject
|
EP2874631A1
(en)
*
|
2012-05-15 |
2015-05-27 |
Cyclacel Limited |
Dosage regimen for sapacitabine and seliciclib
|
BR112014028420A2
(pt)
|
2012-05-16 |
2017-09-19 |
Novartis Ag |
regime de dosagem para um inibidor de quinase pi-3
|
EP2885290B1
(en)
|
2012-06-26 |
2017-10-18 |
Saniona A/S |
A phenyl triazole derivative and its use for modulating the gabaa receptor complex
|
WO2014109858A1
(en)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
US20170000778A1
(en)
|
2013-12-06 |
2017-01-05 |
Emmanuelle di Tomaso |
Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
|
ES2765253T3
(es)
|
2014-02-17 |
2020-06-08 |
Manros Therapeutics |
Compuestos derivados de purina para uso médico
|
DK3148532T3
(en)
|
2014-05-28 |
2021-04-26 |
Piramal Entpr Ltd |
Pharmaceutical Combination Comprising a CDK Inhibitor and a Thioredoxin Reductase Inhibitor for the Treatment of Cancer
|
KR20180073674A
(ko)
|
2015-11-02 |
2018-07-02 |
노파르티스 아게 |
포스파티딜이노시톨 3-키나제 억제제에 대한 투여 요법
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
US10729692B2
(en)
|
2017-02-26 |
2020-08-04 |
Institute For Cancer Research |
Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death
|
WO2018187478A1
(en)
*
|
2017-04-04 |
2018-10-11 |
University Of Miami |
Biomarkers indicative of prostate cancer and treatment thereof
|
SG11202106635WA
(en)
|
2018-12-21 |
2021-07-29 |
Daiichi Sankyo Co Ltd |
Combination of antibody-drug conjugate and kinase inhibitor
|
CN112794852B
(zh)
*
|
2021-01-12 |
2021-11-30 |
江汉大学 |
一种含硒有机化合物及其制备方法与应用
|
CN112794853B
(zh)
*
|
2021-01-12 |
2021-11-30 |
江汉大学 |
一种有机硒化合物及其制备方法与应用
|